GSK’s RSV Vaccine Moves Closer to China Approval
Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year
False
Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
September 1, 2026
7 min read
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
August 31, 2026
4 min read
New approaches to oligonucleotide production, mRNA design, and supply chain control could help turn promising nucleic acid therapies into scalable commercial products
August 31, 2026
4 min read
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
August 27, 2026
9 min read
Why preserving samples is a scientific, regulatory, and operational challenge – and what’s at risk when it goes wrong
False
Affiliations:
Specialties:
Areas of Expertise: